{"id":260320,"date":"2026-05-29T19:38:27","date_gmt":"2026-05-29T19:38:27","guid":{"rendered":"https:\/\/www.europesays.com\/se\/260320\/"},"modified":"2026-05-29T19:38:27","modified_gmt":"2026-05-29T19:38:27","slug":"nyemission-124-mln-kr-teckningskurs-225-kr-ny","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/260320\/","title":{"rendered":"NYEMISSION 124 MLN KR, TECKNINGSKURS 2:25 KR (NY)"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">(Till\u00e4gg: fr\u00e5n fj\u00e4rde stycket)<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Forskningsbolaget Cantargia har beslutat g\u00f6ra en f\u00f6retr\u00e4desemission p\u00e5 124 miljoner kronor.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Det framg\u00e5r av ett pressmeddelande.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Emissionen har teckningskursen 2:25 kronor per aktie vilket kan j\u00e4mf\u00f6ras med torsdagens st\u00e4ngningsnotering 2:92 kronor. Nyemissionen omfattas av teckningsf\u00f6rbindelser och ett garanti\u00e5tagande p\u00e5 totalt cirka 75 miljoner kronor.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">I samband med emissionen har Cantargia ing\u00e5tt ett l\u00e5neavtal med Fenja Capital p\u00e5 upp till 75 miljoner kronor. Som en del av l\u00e5neavtalet ska teckningsoptioner vederlagsfritt emitteras till Fenja Capital.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Likviden ska s\u00e4kra finansiering f\u00f6r inledande av en fas 1b-studie d\u00e4r nadunolimab kombineras med en RAS-h\u00e4mmare, samt fortsatt utveckling och positionering avseende bukspottsk\u00f6rtelcancer, utvidgande av den p\u00e5g\u00e5ende fas 1b-2a-studien samt f\u00f6rberedelser f\u00f6r en fas 2b-studie om myelodysplastiskt syndrom\/akut myeloisk leukemi, samt allm\u00e4nna kostnader.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">B\u00f6rsredaktionen +46 8 51917911 https:\/\/twitter.com\/Borsredaktion<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Nyhetsbyr\u00e5n Direkt<\/p>\n<p><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"(Till\u00e4gg: fr\u00e5n fj\u00e4rde stycket) STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Forskningsbolaget Cantargia har beslutat g\u00f6ra en f\u00f6retr\u00e4desemission p\u00e5 124 miljoner kronor.&hellip;\n","protected":false},"author":2,"featured_media":260303,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,11415,70,71,34,31,33,32,30],"class_list":["post-260320","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-cantargia","tag-economy","tag-ekonomi","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116659559167318738","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/260320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=260320"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/260320\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/260303"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=260320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=260320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=260320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}